We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

125 hedge funds and large institutions have $35.3M invested in Sanofi Contingent Value Rights in 2014 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 27 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% less funds holding

Funds holding: 130 → 125 (-5)

19% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 27

36% less capital inflows, than outflows

Capital inflows: $4.98M | Capital outflows: $7.75M

56% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 16

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
125
Holders Change
-5
Holders Change %
-3.85%
% of All Funds
3.6%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
7
Increased
22
Reduced
27
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

GCVRZ Hedge Fund Activity: Q1 2014 in Review

125 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2014, worth a combined $35.3M — down 15% from $41.5M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of GCVRZ and 7 opened new positions — a net loss of 9 holders — while 27 trimmed existing stakes and 22 added.

The largest buyer was Gruss Capital Management, adding an estimated $929K. The largest seller was Abrams Capital Management, exiting entirely with an estimated $3.96M sold.

  • 125 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2014, down from 130 in Q4 2013.
  • Funds reported $35.3M of Sanofi Contingent Value Rights stock for Q1 2014, down 15% quarter-over-quarter.
  • 7 funds opened new Sanofi Contingent Value Rights positions in Q1 2014 and 16 closed out, a net change of -9 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q1 2014 was Gruss Capital Management, an estimated $929K added.
  • The largest Sanofi Contingent Value Rights seller in Q1 2014 was Abrams Capital Management, an estimated $3.96M sold.

Based on aggregated 13F filings for Q1 2014.